


[Download free pdf] State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 1.: Monoclonal Antibody Therapeutics: ... and Regulatory Space (ACS Symposium Series)

# State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 1.: Monoclonal Antibody Therapeutics: ... and Regulatory Space (ACS Symposium Series)

From American Chemical Society  
ebooks | Download PDF | \*ePub | DOC | audiobook



[Download](#)

[Read Online](#)

#528525 in Books 2016-04-01 Original language: English PDF # 1 6.20 x .60 x 9.10l, .0 #File Name: 0841230269184 pages | File size: 23.Mb

**From American Chemical Society : State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 1.: Monoclonal Antibody Therapeutics: ... and Regulatory Space (ACS Symposium Series)** before purchasing it in order to gauge whether or not it would be worth my time, and all praised State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 1.: Monoclonal Antibody Therapeutics: ... and Regulatory Space (ACS Symposium Series):

Monoclonal antibodies (mAbs) are an important class of therapeutic that has greatly expanded our ability to treat a variety of indications, including cancer, autoimmune disorders, and infectious diseases. The cost of developing these molecules and ensuring that they are fit for purpose is much higher than for small-molecule drugs. Although some of these costs are due in part to the nature of production, a major cost is incurred because of the complexity of the molecule itself. Extensive analytical testing regimes are needed for in-depth characterization and to ensure product stability, proper in-process controls, safety, and efficacy. The next generation of product understanding will require highly complex, orthogonal technologies to elucidate interdependent structure-function relationships. The ACS' focus on this field of research represents a defining moment in the development of technologies for characterizing mAbs. A multitude of experts in the field have come together around a single molecule for the first time to demonstrate both current and future practices involved in the characterization of a biotherapeutic. The current series presents an open discussion of current best practices, a multitude of intuitive research, and a collaborative philosophy on where the field needs to move to satisfy future scientific and regulatory needs. Throughout this effort, a first-of-a-kind repository of regulatory considerations, experimental methods, and data--as well as a widely available "reference"--are now available to industry, academia, regulatory personnel, and instrument manufacturers.

About the Author Dr. John E. Schiel received his B.S. (2004) and Ph.D. (2009) in Chemistry from the University of Nebraska-Lincoln, and is currently a research chemist in the NIST Biomolecular Measurement Division. Dr. Darryl L. Davis holds a doctorate in Medicinal Chemistry from the Philadelphia College of Pharmacy and Science. Currently he leads an analytical group within the discovery organization at Janssen RD. Dr. Oleg V. Borisov earned a B.S. degree (with honors) in Chemistry at Moscow State University (1992), and received his Ph.D. in Chemistry from Wayne State University (1997), after which he completed his post-doctoral studies at Lawrence Berkeley National Laboratories (2000) and Pacific Northwest National Laboratories (2001). He is currently a Director at Novavax, Inc., developing methods and strategies for analysis and characterization of recombinant vaccines, based on nano- and virus-like particle technologies.